Contrarian Corpus
activist conference presentation initial thesis
2023-10-01 · 18 pages

Fortrea Holdings Inc. FTRE

Fortrea, LabCorp's spun-out CRO, earns 9% EBITDA margins versus 18% peers; CEO Tom Pike's IQVIA playbook implies $47-$72 per share, 60-144% upside at normalized margins.

N 4 Narrative
V 3 Visual
C 3 Craft
Original source ↗

Thesis

Fortrea Holdings is a $4bn enterprise-value global contract research organization spun out from LabCorp in 2023, with ~$3bn FY23 revenue, 90+ country footprint, and roughly 7% share of a concentrated CRO market set to grow ~7% annually through 2027. Despite scale comparable to peers like ICON, PPD, and Syneos, Fortrea's FY23 adjusted EBITDA margin guide of 9% sits well below the peer median of 18-19% at comparable scale, reflecting stranded spin-related costs and operational slack that management has pledged to close as TSAs roll off by end-FY24. CEO Tom Pike previously ran Quintiles/IQVIA, where he expanded adjusted EBITDA margins ~425bps and delivered 48% S&P 500 outperformance. Starboard argues that at peer-median 13x EV/EBITDA and normalized margins, Fortrea is worth ~$47 per share at FY24 exit margins (60% upside) or ~$72 at peer margins (144% upside) versus the $29.46 reference price.

SCQA

Situation

Fortrea is a global contract research organization spun out from LabCorp in 2023 with $3bn revenue and 7% share of a concentrated CRO market poised for durable 7% annual growth.

Complication

Fortrea's 9% FY23 EBITDA margin guide lags the 18-19% peer median, driven by post-spin stranded costs and operational slack that roll-off of TSAs and basic execution can close.

Resolution

Support management's margin-improvement roadmap under CEO Tom Pike, who repeated a similar margin playbook at Quintiles/IQVIA, and let operational execution drive rerating toward peer benchmarks.

Reward

At peer-median 13x EV/EBITDA, normalized margins imply ~$47 per share at FY24 exit margins (60% upside) or ~$72 at peer margins (144% upside) from $29.46.

The three reasons

  1. 1

    Fortrea's 9% FY23 EBITDA margin lags CRO peer median of 18-19%

  2. 2

    CEO Tom Pike grew IQVIA margins 425bps and delivered 48% S&P outperformance

  3. 3

    Peer multiples imply ~60-144% upside ($47-$72) at normalized margins

Primary demands

  • Execute on management's stated plan to return to FY22 peer-comparable profitability by end of FY24
  • Drive EBITDA margins from 9% FY23 guide toward the 18% peer median at comparable scale
  • Leverage CEO Tom Pike's proven CRO margin-improvement playbook to unlock multiple rerating

KPIs cited

Adjusted EBITDA margin (FY23 guide)
Fortrea 9% vs peer median 18-19% at comparable scale
Adjusted EBITDA margin (FY22)
Fortrea 13% vs peer median 19% (MEDP 23%, IQV 20%, ICLR 19%)
Enterprise Value
$4bn as of October 13, 2023
FY23 Revenue
~$3bn (91% Clinical Services, 9% Enabling Services)
EV / FY24 EBITDA multiple
Fortrea 12x status quo vs peer median 13x; MEDP 18x, ICLR 13x, IQV 12x, CRL 11x
CRO market share
Fortrea 7% (6th largest); top 7 CROs control over 80%
CRO market growth
~7% CAGR 2022-2027; biopharma R&D 5% annual growth, outsource penetration +60bps/yr
Tom Pike IQVIA margin expansion
+425bps from 11% (FY12) to 15% (LTM Sept 2016)
Tom Pike IQVIA TSR
+90% vs S&P 500 +43% (48% outperformance, May 2013-Oct 2016)
Precedent transaction EBITDA multiples
Median 14x; range 10x-25x across 10 CRO deals 2015-2023
Implied share price
~$47 at 13% FY24 exit margins; ~$72 at 18% peer margins vs $29.46 reference

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • Tom Pike's Quintiles/IQVIA margin expansion (FY12-LTM Sept 2016, +425bps)
  • CRO M&A precedents (LabCorp/Covance, Thermo/PPD, ICON/PRA, EQT/Parexel, PE/Syneos)

Notable slides (5)

Notes

Unusually collaborative/supportive Starboard deck: no villain, no adversarial demand — Starboard endorses incumbent CEO Tom Pike and management's existing margin plan, positioning itself as a validating shareholder. CEO quote on page 12 is used to reinforce (not contradict) the thesis. No stake disclosed in this conference presentation. Filename contains '2023-02-2023' which appears to be a file-naming artifact; deck cover and internal references date the document to October 2023 (Active-Passive Investor Summit).